|
Report Date : |
08.09.2014 |
IDENTIFICATION DETAILS
|
Name : |
TEIJIN PHARMA LTD |
|
|
|
|
Registered Office : |
Kasumigaseki Common Gate West, 3-2-1 Kasumigaseki Chiyodaku 100-0013 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2014 |
|
|
|
|
Date of Incorporation : |
April 2002 |
|
|
|
|
Com. Reg. No.: |
0100-01-078242 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacture of
pharmaceuticals, pharmaceutical devices |
|
|
|
|
No. of Employees : |
1,863 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Slow but correct |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 01, 2014
|
Country Name |
Previous Rating (31.03.2014) |
Current Rating (01.06.2014) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
JAPAN - ECONOMIC OVERVIEW
In the years following World War
II, government-industry cooperation, a strong work ethic, mastery of high
technology, and a comparatively small defense allocation (1% of GDP) helped
Japan develop a technologically advanced economy. Two notable characteristics
of the post-war economy were the close interlocking structures of
manufacturers, suppliers, and distributors, known as keiretsu, and the
guarantee of lifetime employment for a substantial portion of the urban labor
force. Both features are now eroding under the dual pressures of global
competition and domestic demographic change. Japan's industrial sector is
heavily dependent on imported raw materials and fuels. A small agricultural
sector is highly subsidized and protected, with crop yields among the highest
in the world. While self-sufficient in rice production, Japan imports about 60%
of its food on a caloric basis. For three decades, overall real economic growth
had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s,
and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging
just 1.7%, largely because of the after effects of inefficient investment and
an asset price bubble in the late 1980s that required a protracted period of
time for firms to reduce excess debt, capital, and labor. Modest economic
growth continued after 2000, but the economy has fallen into recession three
times since 2008. A sharp downturn in business investment and global demand for
Japan's exports in late 2008 pushed Japan into recession. Government stimulus
spending helped the economy recover in late 2009 and 2010, but the economy
contracted again in 2011 as the massive 9.0 magnitude earthquake and the
ensuing tsunami in March disrupted manufacturing. The economy has largely
recovered in the two years since the disaster, but reconstruction in the Tohoku
region has been uneven. Prime Minister Shinzo ABE has declared the economy his
government's top priority; he has overturned his predecessor's plan to
permanently close nuclear power plants and is pursuing an economic revitalization
agenda of fiscal stimulus, monetary easing, and structural reform. Japan joined
the Trans Pacific Partnership negotiations in 2013, a pact that would open
Japan's economy to increased foreign competition and create new export
opportunities for Japanese businesses. Measured on a purchasing power parity
(PPP) basis that adjusts for price differences, Japan in 2013 stood as the
fourth-largest economy in the world after second-place China, which surpassed
Japan in 2001, and third-place India, which edged out Japan in 2012. The new
government will continue a longstanding debate on restructuring the economy and
reining in Japan's huge government debt, which is exceeding 230% of GDP. To
help raise government revenue and reduce public debt, Japan decided in 2013 to
gradually increase the consumption tax to a total of 10% by the year 2015.
Japan is making progress on ending deflation due to a weaker yen and higher
energy costs, but reliance on exports to drive growth and an aging, shrinking
population pose other major long-term challenges for the economy
|
Source
: CIA |
TEIJIN PHARMA LTD
REGD NAME: Teijin
Pharma KK
MAIN OFFICE: Kasumigaseki
Common Gate West, 3-2-1 Kasumigaseki Chiyodaku 100-0013
Tel:
03-3506-4077 Fax: 03-3506-4498
URL: http://www.teijin-pharma.co.jp
E-Mail
address: (thru the URL)
Mfg of
pharmaceuticals, pharmaceutical devices
85
locations nationwide
USA
(2), UK, Korea, China (2), Spain
Iwakuni
(2)
HIROSHI
UNO, PRES Hidekazu
Kuribayashi, s/mgn dir
Kenichi
Masuda, dir Noriaki
Endoh, dir
Akihisa
Nabeshima, dir Makoto
Yoshida, dir
Yen
Amount: In million Yen, unless
otherwise stated
FINANCES FAIR A/SALES Yen 106,423 M
PAYMENTSSlow
But Correct CAPITAL Yen 10,000 M
TREND UP WORTH Yen 35,565 M
STARTED 2002 EMPLOYES 1,863
MFR OF PHARMACEUTICALS, WHOLLY OWNED BY TEIJIN LTD.
FINANCIAL SITUATION CONSIDERED FAIR
AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
The subject
company was established on the basis of a division separated from Teijin Ltd
(See REGISTRATION). This firm specializes in mfg pharmaceuticals
& medical devices for: bone & joint diseases, respiratory diseases,
cardiovascular & metabolic diseases, other.
In addition, the firm developed home medical care services, home oxygen
therapy continuous positive airway pressure (CPAP) therapy, a treatment for
sleep apnea syndrome, and now holds the largest share in each domestic
market. Entered into market alliance
with Astellas Pharma China Inc, and Astellas Pharma Hong Kong Co Ltd.
The sales
volume for Mar/2014 fiscal term amounted to Yen 106,423 million, a 2% up from
Yen 104,750 million in the previous term.
Home medical care services were in good demand.
The recurring profit was posted at Yen 10,587 million, while
the net loss at Yen 1,526 million, respectively, compared with Yen 17,933
million recurring profit and Yen 7,746 million net profit, respectively, a year
ago. Incurred extraordinary losses at
Yen 8,126 million for this term.
For the
current term ending Mar 2015 the recurring profit is projected at Yen 18,000
million and the net profit at Yen 8,000 million respectively, on a 5% rise in
turnover, to Yen 111,700 million. Gout
drugs and at-home nursing care services will make double-digit growth.
The
financial situation is considered FAIR and good for ORDINARY business
engagements.
Date Registered: Apr 2002
Regd No.: 0100-01-078242 (Tokyo-Chiyodaku)
Legal Status:
Limited Company (Kabushiki Kaisha)
Authorized:
800,000 shares
Issued:
200,000 shares
Sum: Yen 10,000 million
Major shareholders (%):
Teijin Ltd* (100)
*.. Major synthetic textile mfr,
Tokyo, founded 1918, listed Tokyo S/E, capital Yen 70,816 million, sales Yen
784,424 million, operating profit Yen 18,078 million, recurring profit Yen
19,887 million, net losses Yen 8,356 million, total assets Yen 768,411 million,
net worth Yen 281,680 million, employees 15,756, pres Jun Suzuki
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Manufactures pharmaceuticals &
medical devices for: bone & joint diseases, respiratory diseases,
cardiovascular & metabolic diseases; home care medical services, home
oxygen therapy, other (--100%).
Clients: [Mfrs, wholesalers] Teijin Home-Care
Therapy, Kaketsuken Corp, Sakai Inc, Japan Care Service Group, other
No. of
accounts: 500
Domestic
areas of activities: Nationwide
Suppliers: [Mfrs, wholesalers] Teijin Ltd,
Kaketsuken Corp, Fuji Bio Medix, Nichiko Pharma, Morishita Jintan Co, Asuka
Pharmaceutical Co, other
Payment record: slow
but correct
Location: Business
area in Tokyo. Office premises at the
caption address are leased and maintained satisfactorily.
Bank References:
MUFG
(Tokyo & Nihombashi)
Relations:
Satisfactory
(In Million Yen)
|
Terms Ending: |
31/03/2015 |
31/03/2014 |
31/03/2013 |
31/03/2012 |
|
|
Annual
Sales |
|
111,700 |
106,423 |
104,750 |
102,744 |
|
Recur.
Profit |
|
18,000 |
10,587 |
17,933 |
26,411 |
|
Net
Profit |
|
8,000 |
-1,526 |
7,746 |
14,772 |
|
Total
Assets |
|
|
86,748 |
88,309 |
79,667 |
|
Current
Assets |
|
|
45,108 |
50,926 |
44,070 |
|
Current
Liabs |
|
|
32,425 |
34,957 |
30,197 |
|
Net
Worth |
|
|
35,565 |
42,331 |
43,084 |
|
Capital,
Paid-Up |
|
|
10,000 |
10,000 |
10,000 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
|
(%) |
(%) |
(%) |
(%) |
|
S.Growth Rate |
|
4.96 |
1.60 |
1.95 |
3.09 |
|
Current Ratio |
|
.. |
139.11 |
145.68 |
145.94 |
|
N.Worth Ratio |
|
.. |
41.00 |
47.94 |
54.08 |
|
R.Profit/Sales |
|
16.11 |
9.95 |
17.12 |
25.71 |
|
N.Profit/Sales |
|
7.16 |
-1.43 |
7.39 |
14.38 |
|
Return On Equity |
|
.. |
-4.29 |
18.30 |
34.29 |
Notes:
Forecast (or estimated) figures for the 31/03/2015 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.43 |
|
|
1 |
Rs.98.64 |
|
Euro |
1 |
Rs.78.19 |
INFORMATION DETAILS
|
Analysis Done by
: |
SUM |
|
|
|
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.